Related Experiment Video
Updated: May 9, 2026

The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
Published on: March 8, 2019
[Fasudil reverses monocrotaline-induced pulmonary hypertension in rats]
Hui Jiang1, Rui-jin Guan, Hong-yan Wang
1Provincial Clinic College, Fujian Medical University, Cardiovascular Disease Institute, Fujian Provincial Hospital, Fuzhou 350001, China.
Objective:
To observe the effects and related mechanisms of fasudil on monocrotaline-induced pulmonary arterial hypertension (PAH) in rats.
Methods:
A total of 56 healthy male Sprague-Dawley rats were randomly divided into 5 groups: 4 weeks control group (N4), 4 weeks PAH group (M4), 8 weeks control group (N8), 8 weeks PAH group (M8), 8 weeks PAH and fasudil group (F8). PAH was induced by subcutaneous injection of monocrotaline (50 mg/kg). Animals in F8 group received intraperitoneal injection of fasudil hydrochloride (15 mg×kg(-1)×d(-1)) from the end of the 4th week to the end of the 8th week. Rats in control groups and PAH groups received equal volume saline injection. Polyethylene catheters were inserted into the RV through the jugular vein for right ventricular systolic pressure (RVSP) and mean pulmonary artery pressure (mPAP) measurements after various treatment protocols. RV hypertrophy index [RV/(LV+S)] was also measured. Arteries of 50 to 150 µm were evaluated for the median wall thickness and wall area by HE staining as follows: percent wall thickness (WT%) = [(medial thickness×2/external diameter)]×100 and percent wall area (WA%) = (wall area/total area)×100%. The mRNA expression of ROCK-1 in lung tissue was analyzed by reverse transcription-polymerase chain reaction (RT-PCR). The protein expressions of ROCK-1 and MYPT-1 in lung tissue were analyzed by Western blot and MYPT-1 phosphorylation, respectively.
Results:
Forty-one rats survived and mortality rate was zero in N4, N8 and M4 groups. Survival rate was significantly higher in F8 group compared to M8 group (75.00% vs. 31.25%, P < 0.05). At the end of the 4th week, RVSP [(62.25 ± 3.24) vs. (31.33 ± 2.35) mm Hg(1 mm Hg = 0.133 kPa)], mPAP [(36.38 ± 2.31) vs.(20.32 ± 1.81) mm Hg], [RV/(LV+S)] (0.5648 ± 0.0580 vs. 0.3458 ± 0.0455), WT% [(25.63 ± 5.35)% vs.(13.38 ± 3.45)%], WA% [(60.36 ± 2.51)% vs. (38.42 ± 2.84)%] were all significantly higher in M4 group than in N4 group (all P < 0.01). RVSP [(54.64 ± 4.11) vs. (67.37 ± 4.68) mm Hg], mPAP [(26.25 ± 2.32) vs. (39.83 ± 1.83) mm Hg], and markedly relieve [RV/(LV+S)] (0.3985 ± 0.0210 vs. 0.7600 ± 0.0341), WT% [(15.64 ± 2.81)% vs. (28.26 ± 4.38)%], WA% [(40.35 ± 2.82)% vs. (68.83 ± 1.63)%] were all significantly lower in F8 group than in M8 group (all P < 0.05) while the expression of ROCK-1 mRNA (1.2139 ± 0.1778 vs. 1.6839 ± 0.3251, P < 0.01), and the protein expression of ROCK-1 and MYPT-1 as well as the extent of MYPT-1 phosphorylation were all downregualted in F8 group compared to M8 group (all P < 0.01).
Conclusions:
Fasudil can effectively reverse the MCT-induced PAH in rats via downregulating ROCK-1 and MYPT-1.
Insights
Fasudil effectively reverses monocrotaline-induced pulmonary arterial hypertension (PAH) in rats by reducing ROCK-1 and MYPT-1 expression. This treatment improved survival rates and key hemodynamic parameters in PAH models.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Pulmonary Medicine
Background:
- Pulmonary arterial hypertension (PAH) is a severe condition characterized by high blood pressure in the pulmonary arteries.
- Monocrotaline (MCT) is a toxin commonly used to induce experimental PAH in animal models.
- Rho-kinase (ROCK) signaling pathways are implicated in the pathogenesis of PAH.
Purpose of the Study:
- To investigate the therapeutic effects of fasudil on monocrotaline-induced pulmonary arterial hypertension (PAH) in a rat model.
- To elucidate the underlying mechanisms, specifically the role of ROCK-1 and MYPT-1, in fasudil's action on PAH.
Main Methods:
- Rats were induced with monocrotaline (MCT) to develop PAH.
- Fasudil hydrochloride was administered to a subset of PAH rats during the established disease phase.
- Hemodynamic parameters (RVSP, mPAP), right ventricular hypertrophy, pulmonary artery wall remodeling, and ROCK-1/MYPT-1 expression (mRNA and protein) were assessed.
Main Results:
- Fasudil treatment significantly improved survival rates in MCT-induced PAH rats compared to untreated controls.
- Fasudil administration markedly reduced right ventricular systolic pressure, mean pulmonary artery pressure, and right ventricular hypertrophy.
- Fasudil downregulated the expression of ROCK-1 mRNA and protein, as well as MYPT-1 protein and its phosphorylation in lung tissue.
Conclusions:
- Fasudil demonstrates significant efficacy in reversing established monocrotaline-induced pulmonary arterial hypertension in rats.
- The therapeutic effects of fasudil are associated with the downregulation of the ROCK-1 and MYPT-1 signaling pathway.
- Fasudil represents a potential therapeutic agent for PAH, targeting key molecular mechanisms involved in vascular remodeling and vasoconstriction.
More Related Videos
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
09:23Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension
Published on: February 11, 2017
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System